Compare Cytokinetics Inc (CYTK) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Monster Beverage Corp — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.50B), while Monster Beverage Corp trades at $43.6 (market cap $84.00B). The key difference: Monster Beverage Corp is far larger — about 9.9× Cytokinetics Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Monster Beverage Corp for 72 Days on average.
| CYTK | MNST | |
|---|---|---|
Market Cap | $8.50B | $84.00B |
Volume | 2,395,556 | 8,371,981 |
Sector | Health | Consumer Staples |
52-Week High | $87.26 | $49.97 |
52-Week Low | $54.76 | $33.16 |
Typical Hold Time | 19 Days | 72 Days |
Enterprise Value | $8.60B | $82.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Monster Beverage (MNST) trades at $42.88, down 0.86% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported robust Q2 2026 earnings, beating estimates with $0.30 EPS, and maintains impressive profitability metrics including 55.55% gross margin and 23.08% net income margin. Recent news highlights Monster's debt-free balance sheet and international expansion driving 35% overseas sales growth.
While valuation multiples appear elevated (P/E 39.7, P/S 9.18), Monster's consistent earnings beats and analyst consensus price target of $98.22 suggest significant upside potential. Key risks include regulatory challenges in international markets and competitive pressures, but the company's strong cash flow generation and market position support long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
